X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VTP-200 is an investigational immunotherapeutic combination regimen consisting of an initial dose using the ChAdOx vector and a second dose using MVA vector, both encoding the same HPV antigens. It is being evaluated for high-risk HPV infections in women.
Lead Product(s): VTP-200
Therapeutic Area: Infections and Infectious Diseases Product Name: HPV001
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
Details:
The partnership aims to fast-track the development of a vaccine candidate known as VTP-500 for the prevention of Middle East Respiratory Syndrome, the often fatal disease caused by the MERS coronavirus.
Lead Product(s): VTP-500
Therapeutic Area: Infections and Infectious Diseases Product Name: VTP-500
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: CEPI
Deal Size: $34.8 million Upfront Cash: Undisclosed
Deal Type: Partnership December 21, 2023
Details:
VTP-850 (ChAdOx1-PCAQ) is a next-generation prostate cancer immunotherapeutic candidate which utilizes Vaccitech’s sequential dosing approach of two proprietary nonreplicating viral vectors, ChAdOx and MVA.
Lead Product(s): ChAdOx1-PCAQ,MVA-PCAQ
Therapeutic Area: Oncology Product Name: VTP-850
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
VTP-300 (MVA-HBV) is a first antigen-specific immunotherapy consists of an initial dose using the ChAdOx platform and a secondary dose using MVA encoding multiple hepatitis B antigens, including full-length surface, modified polymerase and core antigens.
Lead Product(s): MVA-HBV,ChAdOx1-HBV,Nivolumab
Therapeutic Area: Infections and Infectious Diseases Product Name: VTP-300
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
VTP-200 is an investigational heterologous prime boost immunotherapy consisting of an initial dose using the ChAdOx vector and a second dose using MVA, both encoding the same HPV antigens, to elicit an immune response to HPV.
Lead Product(s): VTP-200
Therapeutic Area: Infections and Infectious Diseases Product Name: VTP-200
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2023
Details:
VTP-300 administered as a monotherapy or in combination with a single administration of low-dose nivolumab at the time of the booster dose was administered with no treatment-related serious adverse events and infrequent transient transaminitis.
Lead Product(s): MVA-HBV,ChAdOx1-HBV,Nivolumab
Therapeutic Area: Infections and Infectious Diseases Product Name: VTP-300
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
VTP-300 (also named as MVA-HBV), is a novel immunotherapy, dosed in a prime-boost regimen, whereby the immune system is primed with an adenovirus (ChAdOx) and boosted with a pox virus (MVA).
Lead Product(s): MVA-HBV,ChAdOx1-HBV,Nivolumab
Therapeutic Area: Infections and Infectious Diseases Product Name: VTP-300
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
Details:
Meaningful, durable reductions of Hepatitis B surface antigen (HBsAg) were seen in some patients who received VTP-300 (MVA-HBV) as either a monotherapy or in combination with a single low dose of nivolumab at the booster dose.
Lead Product(s): MVA-HBV,ChAdOx1-HBV,Nivolumab
Therapeutic Area: Infections and Infectious Diseases Product Name: VTP-300
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
AB-729 is an RNA interference therapeutic specifically designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.
Lead Product(s): AB-729,VTP-300
Therapeutic Area: Infections and Infectious Diseases Product Name: AB-729
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Arbutus Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
The acquisition of Avidea strengthens Vaccitech’s position as a leader in immunotherapies and vaccines including SNAPvax CV, using the SNAPvaxTM platform uses self-assembly to co-deliver multiple antigens and immunomodulators in nanoparticles of precise size and composition.
Lead Product(s): SNAPvax Cancer Vaccine
Therapeutic Area: Oncology Product Name: SNAPvax CV
Highest Development Status: IND EnablingProduct Type: Vaccine
Recipient: Avidea Technologies
Deal Size: $40.0 million Upfront Cash: $12.5 million
Deal Type: Acquisition December 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
